



RHINO-CEREBRAL MUCORMYCOSIS: A CASE REPORT

Tejas Rane	Junior Resident, Department of Medicine, Krishna Institute of medical sciences Deemed to be University, Karad, 415110.
Virendra C. Patil*	Professor and Head of Department of Medicine, Krishna Institute of medical sciences Deemed to be University, Karad, 415110. *Corresponding Author
Akshay Kale	Junior Resident, Department of Medicine, Krishna Institute of medical sciences Deemed to be University, Karad, 415110.

ABSTRACT Rhino-cerebral mucormycosis is a rare, invasive fungal infection caused by fungi of the order Mucorales and class of mucormycetes. It is one of the diseases that remain poorly understood with high mortality rate. Presently, the triad of clinician's awareness prompt initiation of treatment and timely surgical intervention is the effective way of managing the disease. We report a case of 52 year old female with diabetes mellitus with history of fever, peri-orbital oedema, ptosis, ophthalmoplegia and ulcers in hard palate. Patient was diagnosed to have Rhino-cerebral mucormycosis with cavernous sinus extension. She was treated with intravenous Amphotericin B, insulin, Functional endoscopic sinus surgery (FESS) and debridement. She was given intravenous antifungal therapy followed by oral antifungal. Patient showed significant improvement.

KEYWORDS : Rhino-cerebral mucormycosis, Diabetes mellitus, ophthalmoplegia, Amphotericin B

INTRODUCTION:

Mucormycosis is a rare, invasive, life threatening fungal infection caused by fungi of the order Mucorales and class of mucormycetes. It's ubiquitous in nature and abundant in our environment. It is highly concentrated near construction activities, decaying vegetables and organic material, soils etc. Mucorales's growth is favored in tropical countries as temperature and humidity supports sporulation. Inhalations of spores infect humans.^[1,2] The sites of pre-dilection for this infection are the nose and para-nasal sinuses, it progresses to involve the orbit and at times in the intracranial structures such as the cavernous sinus and the cerebral hemispheres.^[3] Rhino-orbito-cerebral mucormycosis mainly occurs in immuno-compromised patients. Poorly controlled diabetics, immune-suppression, hematological malignancy and iron over load are some of the conditions which predispose patients to the development of this disease.^[4] The fungi are vaso-invasive and locally destructive but their main pathogenic mechanism is growth along the blood vessels, invasion of the lumen and formation of mycotic thrombi which are said to lead to mycotic emboli.^[4,5] Within the orbit, the mucorales cause extensive invasion on the extra ocular muscles and may lead to ophthalmoplegia and can form progression in cavernous sinus.⁷ We are report a case of rhino-cerebral mucormycosis.

CASE REPORT:

A 52 year female admitted with history of fever along with chills for last 7-8 days, swelling, weakness and numbness on right side of face for last 3-4 days. On examination patient was conscious oriented, afebrile, vitals were stable, no meningeal sign, ptosis of right eye, right side lid oedema, right eye external and internal ophthalmoplegia (3rd, 4th, 6th nerves) with vision of 6/6 (Table.1), right maxillary tenderness right LMN (lower motor neuron) facial palsy (Figure 1), and ulcers over hard palate (Figure 2).

Figure 1: Right sided ptosis with periorbital edema and right sided facial palsy



Figure 2: Ulcers and Perforation in the right anterior region of the hard palate





Table 1: Examination and comparison of right and left eye

	Right	Left
Tenderness	Absent	Absent
Eyelids	Ptosis Periorbital oedema: present Temperature : normal	Normal
Vision	Normal	Normal
Pupils	Fixed	Normal, reacting to light
Extra ocular movements	Total restriction in all direction	Full and free in all direction


Table 2: Patient laboratory reports

Random blood sugar	343 mg/dl,
Urine ketone bodies	Negative
Serum creatinine	0.9 mg/dl
Haemoglobin	10.4gm%
Total leukocyte count	23700/μl
Erythrocyte sedimentation rate	60 at the end of 1 hour
C- reactive protein titers	Positive


Figure 3: MRI Brain with PNS contrast: T2 weighted image shows hyperintense region in right maxillary sinus, ethmoidal sinus, sphenoid sinus with subtle erosions of bone extending to right nasal cavity, hard palate, floor of orbit, with right cavernous sinus invasion.



Based on history, clinical findings and investigations (Table 2) patient was diagnosed to be Rhino-cerebral mucormycosis with cavernous sinus extension. Patient was started on antibiotics, insulin, and Amphotericin B. Surgical intervention in the form of functional endoscopic sinus surgery (FESS) and debridement was done. Sample was sent for histopathology, KOH mount, fungal culture and antibiotic sensitivity. KOH mount was negative for fungal elements. Histopathology report revealed thick walled ribbon like aseptate hyphal elements that branch at right angle which confirmed the diagnosis of mucormycosis (Figure 4).



After surgical intervention (FESS) and medical therapy patient has showed significant improvement in cranial nerve palsies with decreased periorbital swelling. Patient was given Amphotericin B for 15 days. Patient was discharged on tablet Itraconazole. Healing plates for hard palate ulcers were given for further healing and support. On one month of follow-up improvement was seen with ptosis reduced, periorbital swelling decreased, extra-ocular movement improved and right side LMN (VIIth) palsy reduced (Figure 5).



DISCUSSION:

Rhino-cerebral mucormycosis is rare an opportunistic fungal infection caused by fungal spores which are ubiquitous in nature. In India, diabetic patient outnumbered other risk factors for getting mucormycosis. Many of the diabetic patients are unaware about diabetic status and presented with mucormycosis.^[6]

Sites of mucormycosis lesion are rhino-orbital-cerebral mucormycosis involving paranasal sinuses, orbit with intracranial extension, pulmonary, cutaneous, gastrointestinal, disseminated and others like isolated renal in immune-competent host, brain abscess, endocarditis in IV drug users etc. High index of suspicion is required for the diagnosis of mucormycosis, mainly due to non-specific clinical features and culture which can be sterile in up to 50% of cases due to aseptate fungus being damaged during tissue handling in laboratory.^[5,6]

The infection usually results from entry through nose and spreading to para-nasal sinuses.^[8,9]

The infection can be divided into 3 stages:

Stage 1: It occurs after inhaled spores infect the para-nasal sinus. Necrotic lesion usually appears on nasal mucosa, turbinate and hard palate. It causes nasal discharge and nasal blockade and progressive formation of necrotic eschar on the mucosa of the nose, most frequently on the middle and inferior turbinate. Epistaxis can be a sign in this stage.

Stage 2: Orbito-facial infection occurs by either direct extension through nose and maxillary sinus or through the blood vessels. Signs and symptoms can be facial pain, facial anesthesia, proptosis, orbital edema and facial cellulitis and complete ophthalmoplegia.

Stage 3: Infections spread intracranially via the cribriform plate or orbital apex. By the time orbital involvement becomes manifest 80% of the patients already have meningeal involvement. Intracranial extension can cause meningitis, cerebritis, infarction, abscess formation, cavernous vein thrombosis and internal carotid thrombosis. Neurological manifestations are usually nonspecific but focal sign of cavernous sinus or internal carotid artery thrombus may be present.^[10,11]

The definitive laboratory diagnosis of rhino-cerebral mucormycosis requires tissue diagnosis. The classical histological appearance is large, broad, non-separate hyphae with right angle branching and distinct vascular invasion.

Treatment principles include:

1. Early diagnosis.
2. Reversal or control of precipitating cause like correction of diabetic ketoacidosis, minimization of immunosuppressions if possible etc.
3. Antifungal therapy: Amphotericin B, Posaconazole, Isavuconazole
4. surgical debridement/ excision of lesion
5. Adjuvant therapy: Hyperbaric oxygen, Deferasirox, Caspofungin statins.^[9]

At present, antifungal therapy and aggressive surgical intervention are used to treat mucormycosis. Based on retrospective clinical studies, amphotericin B is currently used as the first-line antifungal agent. Several case reports have documented that patients with rhino-cerebral mucormycosis were successfully treated by amphotericin B.^[10,11] Unfortunately, despite antifungal therapy and disfiguring surgical debridement, the overall mortality of mucormycosis patients remains high and approaches 40% in diabetic patients with rhino-cerebral mucormycosis.^[2]

In present case mucormycosis being one of the first differential diagnoses. Patient was diagnosed early with clinical presentation and investigation. Amphotericin B along with surgical debridement (FESS) was done early. Histopathology report relived the diagnosis of mucormycosis. Improvement was seen 10 days of Amphotericin B therapy along with surgery. Inj. Amphotericin B was given for 15 days followed by tab. Itraconazole on discharge. Patient blood sugar levels were well controlled. Patient improved significantly on follow-up. The supportive healing plates were advised for ulcers. A similar case series was reported by Rasoul Mohammadi et al in 2015, all 3 cases had hyperglycemic state, were diagnosed as rhino-cerebral mucormycosis. All patients were treated similarly with antifungal therapy and surgical debridement.^[12] Similarly Ya-Chun Hsiao et al in 2002 reported a case of 64 year female patient with type 2 Diabetes mellitus with ketoacidosis diagnosed as rhino-cerebral mucormycosis and was treated with antifungal therapy and surgical debridement.^[13]

CONCLUSIONS:

Mucormycosis has been reported from various parts of the world. Rhino-cerebral mucormycosis although a rare entity, should be kept in mind when handling cases with orbital cellulites, cavernous sinus thrombosis and invasive sinusitis, especially in patients with immunocompromised state including diabetes mellitus. Early diagnosis, surgical excision, appropriate debridement, suitable antifungal therapy, and treating the underlying co-morbidity will result in better outcome of the disease and better survival rate.

REFERENCES:

1. Nithyanandam S, Jacob MS, Battu RR et al Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian journal of ophthalmology.2003.51:231-6.
2. Cheng VC, Chen JH, Wong SC, et al. Hospital Outbreak of Pulmonary and Cutaneous Zygomycosis due to Contaminated Linen Items From Substandard Laundry. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 62:714-21
3. Yanagisawa E, Friedman S, Kundargi RS et al: Rhinocerebral phycomycosis. Laryngoscope 1977; 87: 1319-35.
4. Ferguson BJ. Mucormycosis of the nose and the paranasal sinuses. Otolaryngol Clin N

- Am 2000;33:349–65.
5. Yousem DM, Galetta LS et al finding in rhino-cerebral mucormycosis. *J Computer Assist Tomography* 2001; 13:878–82.
 6. Hosseini, Borghei. Rhinocerebral mucormycosis: pathways of spread. *Eur Arch Otorhinolaryngol*. 2005;262:932-8.
 7. Bhansali A, Bhadada S, Sharma A et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. *Post Grad Med Journal* 2004; 80: 670-4.
 8. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. *The Journal of antimicrobial chemotherapy* 2012;67:715-22.
 9. Soman R, Gupta N et al. Deferasirox in mucormycosis: hopefully, not defeated. *The Journal of antimicrobial chemotherapy* 2012;67:783-4.
 10. Cagatay AA, Oncü SS et al Rhino-; cerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: A case report. *BMC Infect Dis*. 2001;222001.
 11. Ericsson M, Anniko M et al. A case of chronic progressive rhino-cerebral mucormycosis treated with liposomal amphotericin B and surgery. *Clinical Infectious Disease*. 2002 585–586.
 12. Rasoul Mohammadi, Mohsen Meidani et al. Case series of rhino-cerebral mucormycosis occurring in diabetic patients. *Caspian J Intern Med*. 2015 Autumn; 6(4):243–246.
 13. Ya-Chun Hsiao, Kun-Wu Tsan et al. Rhinocerebral Mucormycosis in Diabetes: A Case Report. *J Intern Med Taiwan* 2002;13: 160-164) *J Intern Med Taiwan* 2002;13: 160-164.